AceLink Announces First Patient Dosed in Phase 2 Trial of AL01211 in Fabry Disease
AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs), announced today that the first patient has been dosed with AL01211 in its Phase 2 trial in China in patients with Fabry disease.
AceLink Opens First Clinical Site in China for Phase 2 Study in Fabry Disease
AceLink Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced the opening of the first clinical trial site in China for its Phase 2, open‑label study of the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary measures of physiological efficacy of AL01211 in males with classic Fabry disease who have not been previously treated with other Fabry disease therapies. AceLink is developing the next generation oral substrate reduction therapies (SRTs) to address significant unmet medical needs and improve the quality of life of patients with inherited disorders of glycosphingolipid metabolism....
AceLink Therapeutics Receives FDA Clearance to Initiate a Phase 2 Study of AL1211 in Patients with Fabry Disease
Phase 2 trial is a randomized, dose-blinded, active-controlled, dose-ranging study of the safety and pharmacological activity of AL1211 in male patients with classic Fabry disease...
AceLink Therapeutics to Present at World Orphan Drug Congress USA
AceLink Therapeutics, Inc., a clinical stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs) to address significant unmet medical needs and improve the quality of life of patients with inherited disorders of glycosphingolipid metabolism...
AceLink Therapeutics Appoints Pedro Huertas, M.D., Ph.D., as Chief Medical Officer
AceLink Therapeutics, Inc., a clinical stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs) to address significant unmet medical needs and improve the quality of life of patients with inherited disorders of glycosphingolipid metabolism, today announced the appointment of Pedro Huertas, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Huertas is a distinguished expert in rare diseases and will serve as an important resource for AceLink as the company advances its development pipeline.
AceLink Presents Phase 1 Study of AL01211 to Treat Fabry Disease at WORLD Symposium
AceLink Therapeutics, Inc. (AceLink), an innovative biopharmaceutical company developing transformative therapies for genetic diseases, today presented positive data from a Phase 1 trial evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL01211 in healthy volunteers.
AceLink Presents Preclinical Data on AL00804 at WORLD Symposium
AceLink Therapeutics, Inc. (AceLink), an innovative biopharmaceutical company developing transformative therapies for genetic diseases, today presented data on the development of AL00804, a novel brain penetrant glucosylceramide synthase inhibitor, to treat Gaucher disease and other neuronopathic glycosphingolipid (GSL) storage diseases. AL00804 is a novel, oral, highly brain penetrant glucosylceramide synthase inhibitor (GCSi).
AceLink Therapeutics to present two posters on Fabry Disease and Gaucher Disease at 2023 WORLD Symposium
AceLink Therapeutics, Inc. (AceLink), an innovative biopharmaceutical company developing transformative therapies for genetic diseases, today announced that the company will present two abstracts featuring the development of AL01211 to treat Fabry disease and AL00804 to treat Gaucher disease and other neuronopathic glycosphingolipid storage diseases at the 19th Annual World Symposium Conference, being held in Orlando, Florida, from February 22-26, 2023.
